The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
Frontiers in Pharmacology · 21.02.2023 · 14
DOI: 10.3389/fphar.2023.1080117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.02.2023. Verfasst von Ping Siu Kee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pharmacogenetics has potential for optimizing use of psychotropics. CYP2D6 and CYP2C19 are two clinically relevant pharmacogenes in the prescribing of antidepressants. Using cases recruited from the Understanding Drug Reactions Using Genomic Sequencing (UDRUGS) study, we aimed to evaluate the clinical utility of genotyping CYP2D6 and CYP2C19 in antidepressant response. Genomic and clinical data for patients who were prescribed antidepressants for mental health disorders, and experienced adverse reactions (ADRs) or ineffectiveness, were extracted for analysis. Genotype-inferred phenotyping of CYP2D6 and CYP2C19 was carried out as per Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. A total of 52 patients, predominantly New Zealand Europeans (85%) with a median age (range) of 36 years (15–73), were eligible for analysis. Thirty-one (60%) reported ADRs, 11 (21%) ineffectiveness, and 10 (19%) reported both. There were 19 CYP2C19 NMs, 15 IMs, 16 RMs, one PM and one UM. For CYP2D6, there were 22 NMs, 22 IMs, four PMs, three UMs, and one indeterminate. CPIC assigned a level to each gene-drug pair based on curated genotype-to-phenotype evidence. We analyzed a subgroup of 45 cases, inclusive of response type (ADRs/ineffectiveness). Seventy-nine (N = 37 for CYP2D6 , N = 42 for CYP2C19 ) gene-drug/antidepressant-response pairs with CPIC evidence levels of A, A/B, or B were identified. Pairs were assigned as ‘actionable’ if the CYP phenotypes potentially contributed to the observed response. We observed actionability in 41% (15/37) of CYP2D6 -antidepressant-response pairs and 36% (15/42) of CYP2C19 -antidepressant-response pairs. In this cohort, CYP2D6 and CYP2C19 genotypes were actionable for a total of 38% pairs, consisting of 48% in relation to ADRs and 21% in relation to drug ineffectiveness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.
- Department of Pathology, Center for Personalized Medicine, Children's Hospital Los Angeles, Los Angeles, CA, United States.
- Department of Medicine, University of Otago, Christchurch, New Zealand.
- Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand.
Zitieren
APA
Kee, P. S., Maggo, S. D. S., Kennedy, M. A., & Chin, P. K. L. (2023). The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1080117
Vancouver
Kee PS, Maggo SDS, Kennedy MA, Chin PKL. The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1080117
BibTeX
@article{Kee2023,
author = {Kee, Ping Siu and Maggo, Simran D S and Kennedy, Martin A and Chin, Paul K L},
title = {The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1080117}
}
EUVIMED